ALCLOXA

US Approved OTC

First approved in 1961

Details

Stereochemistry	RACEMIC
Molecular Formula	C4H5N4O3.2Al.Cl.4HO
Molecular Weight	314.553
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-].NC(=O)NC1NC(=O)[N-]C1=O

InChI

InChIKey=IMZDRXBSGZPLDE-UHFFFAOYSA-H

InChI=1S/C4H6N4O3.2Al.ClH.4H2O/c5-3(10)6-1-2(9)8-4(11)7-1;;;;;;;/h1H,(H5,5,6,7,8,9,10,11);;;1H;4*1H2/q;2*+3;;;;;/p-6

HIDE SMILES / InChI

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Al
Molecular Weight	26.9815
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H6N4O3
Molecular Weight	158.1154
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://biotechnologia.pl/uploads/biotechnologia/product/leaflet/156476/info_20ALCLOXA.pdfhttp://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34714 | https://www.ncbi.nlm.nih.gov/pubmed/26620883
Curator's Comment: description was created based on several sources, including: http://tri-k.com/acloxa

Aldioxa is the generic name for the metal complex, dihydroxyaluminum allantoinate, which is hydrolyzed to allantoin and aluminium hydrate at the gastric mucosa. Aldioxa was approved in Japan to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. It was discovered, that aldioxa ameliorates delayed gastric emptying through its antagonistic activity on the α-2 adrenergic receptor. The most commonly reported adverse reactions include constipation.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Alpha-2a adrenergic receptor 63 Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883	Antagonist 2778

Conditions

Condition	Modality	Highest Phase	Product
Chaffing 5 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa716980-803d-4d33-8fce-ee7aa6da0830	Preventing	Not Provided 504	BODYGLIDE FOR HER Approved Use helps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns. Launch Date 1.25902075E12
Functional dyspepsia 12 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883	Primary	Preclinical	Unknown Approved Use Unknown
Gastric ulcer 67 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883	Primary	Approved 8429	Unknown Approved Use protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Duodenal ulcer 42 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883	Primary	Approved 8429	Unknown Approved Use protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Gastritis 45 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883	Primary	Approved 8429	Unknown Approved Use protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.

C_max

Value	Dose	Co-administered	Analyte	Population
6.43 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/	10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:		ALLANTOIN plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
30 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/	10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:		ALLANTOIN plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/	10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:		ALLANTOIN plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:15676	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:15676
ChemicalBook	CB3215461	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3215461
MolPort	MolPort-001-779-876	https://www.molport.com/shop/molecule-link/MolPort-001-779-876
eMolecules	476195	https://www.emolecules.com/cgi-bin/more?vid=476195

PubMed

Title	Date	PubMed
[Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. I. Toxicity].	1962 Jul-Aug	14017699
[Evaluation of the anti-ulcer drugs using image analysis technology: effect of aldioxa containing preparation on the experimental gastric ulcer in rats].	1989 Nov	2613107
[The effect of aldioxa on the formation of gastritis induced with sodium hydroxide].	1990 Nov	2279713
[Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of aldioxa on gastric lesions].	1994 Mar	8144103
Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia.	2015 Dec 1	26620883

Sample Use Guides

In Vivo Use Guide

Antiperspirants, deodorants: Creams, spray, lossions: 0.25-0.5% Baby products: creams; powders: 0.2-0.5%

Route of Administration: Topical

In Vitro Use Guide

In vitro Alcloxa inhibited formation and bacterial decomposition of pulverized human epidermal scales. The scales were obtained from patient with exfoliative dermatitis, characterized by a great deal of exudation. The scales were were pulverized in a Wiley mill, defatted with ether and suspended in a 0,2% Alcloxa solution.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:07:01 UTC 2023` Edited by `admin` on `Fri Dec 15 19:07:01 UTC 2023`
Record UNII	18B8O9DQA2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ALCLOXA

Official Name

English

ALUMINIUM, CHLOROTETRAHYDROXY((4,5-DIHYDRO-2-HYDROXY-5-OXO-1H-IMIDAZOL-4-YL)UREATO)DI-

Common Name

English

CHLOROTETRAHYDROXY((2-HYDROXY-5-OXO-2-IMIDAZOLIN-4-YL)UREATO)DIALUMINIUM

Common Name

English

ALCLOXA [INCI]

Common Name

English

Chlorotetrahydroxy[(2-hydroxy-5-oxo-2-imidazolin-4-yl)ureato]dialuminum

Common Name

English

ALLANTOLOX

Brand Name

English

RC-173

Code

English

ALUMINIUM CHLORHYDROXY ALLANTOINATE

Common Name

English

ALCLOXA [JAN]

Common Name

English

ALCLOXA [MART.]

Common Name

English

ALCLOXA [USAN]

Common Name

English

ALUMINUM CHLORHYDROXY ALLANTOINATE

Common Name

English

Alcloxa [WHO-DD]

Common Name

English

ALUMINUM CHLOROHYDROXY ALLANTOINATE

Common Name

English

alcloxa [INN]

Common Name

English

ALUMINUM CHLORHYDROXY ALLANTOINATE [II]

Common Name

English

ALCLOXA [VANDF]

Common Name

English

ALUMINUM, CHLOROTETRAHYDROXY((4,5-DIHYDRO-2-HYDROXY-5-OXO-1H-IMIDAZOL-4-YL)UREATO)DI-

Common Name

English

ALUMINIUM CHLOROHYDROXY ALLANTOINATE

Common Name

English

ALCA

Code

English

Classification Tree Code System Code

CFR

21 CFR 346.20

Created by admin on Fri Dec 15 19:07:01 UTC 2023 , Edited by admin on Fri Dec 15 19:07:01 UTC 2023

NCI_THESAURUS

C29700

Created by admin on Fri Dec 15 19:07:02 UTC 2023 , Edited by admin on Fri Dec 15 19:07:02 UTC 2023

EPA PESTICIDE CODE

85703

Created by admin on Fri Dec 15 19:07:01 UTC 2023 , Edited by admin on Fri Dec 15 19:07:01 UTC 2023

Code System Code Type Description

NCI_THESAURUS

C76518

Created by admin on Fri Dec 15 19:07:02 UTC 2023 , Edited by admin on Fri Dec 15 19:07:02 UTC 2023

PRIMARY

RXCUI

1305554

Created by admin on Fri Dec 15 19:07:02 UTC 2023 , Edited by admin on Fri Dec 15 19:07:02 UTC 2023

PRIMARY

RxNorm

CAS

1317-25-5

Created by admin on Fri Dec 15 19:07:01 UTC 2023 , Edited by admin on Fri Dec 15 19:07:01 UTC 2023

PRIMARY

ECHA (EC/EINECS)

215-262-3

Created by admin on Fri Dec 15 19:07:01 UTC 2023 , Edited by admin on Fri Dec 15 19:07:01 UTC 2023

PRIMARY

FDA UNII

18B8O9DQA2

Created by admin on Fri Dec 15 19:07:01 UTC 2023 , Edited by admin on Fri Dec 15 19:07:01 UTC 2023

PRIMARY

SMS_ID

100000087735

Created by admin on Fri Dec 15 19:07:02 UTC 2023 , Edited by admin on Fri Dec 15 19:07:02 UTC 2023

PRIMARY

DRUG BANK

DB11205

Created by admin on Fri Dec 15 19:07:01 UTC 2023 , Edited by admin on Fri Dec 15 19:07:01 UTC 2023

PRIMARY

EVMPD

SUB05301MIG

Created by admin on Fri Dec 15 19:07:01 UTC 2023 , Edited by admin on Fri Dec 15 19:07:01 UTC 2023

PRIMARY

DAILYMED

18B8O9DQA2

Created by admin on Fri Dec 15 19:07:01 UTC 2023 , Edited by admin on Fri Dec 15 19:07:01 UTC 2023

PRIMARY

INN

1633

Created by admin on Fri Dec 15 19:07:01 UTC 2023 , Edited by admin on Fri Dec 15 19:07:01 UTC 2023

PRIMARY

Related Record Type Details


					3XHB1D032B

ALUMINUM CATION

ACTIVE MOIETY


					344S277G0Z

Allantoin

ACTIVE MOIETY


					18B8O9DQA2

ALCLOXA

ACTIVE MOIETY

Details

SMILES

InChI

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Approved Use

Approved Use

Approved Use

Cmax

AUC

T1/2

Sourcing

PubMed

Sample Use Guides

C_max

T_1/2